Megachem Limited Overview
Megachem is a small-cap Singapore specialty chemicals distributor. It sits between global chemical producers and more than 2,000 industrial customers, mostly multinationals, across Asia, Europe, the Middle East and Australia. It carries over 1,000 types and grades of specialty chemicals. Revenue is spread across coatings and polymers, surface technology, biotech/life sciences, advanced polymer composites and resources/oil and gas. A small contract-manufacturing and custom-blending arm (about 3% of revenue) supports the distribution business. The group has its own warehousing and blending infrastructure in Singapore, offices in 12 countries and a 36.19% stake in its SET-listed Thai associate. Japanese trading house Chori owns 29.99%. Revenue has stayed between S$123m and S$144m since 2021. Margins are thin and cyclical, and working-capital needs are high. The 2023 warehouse fire, now rebuilt, distorted profits from FY2023 to FY2025 and also forced the first capex cycle in more than a decade.
Company's own description
Megachem's filings describe it as a one-stop specialty chemical solutions provider, established in 1988. It provides integrated value-added services, including distribution and contract manufacturing of specialty chemicals, to meet customer requirements. The company says it distributes over 1,000 types and grades of specialty chemicals to more than 2,000 industrial customers, mostly well-known multinationals. It names its end-industries as water treatment, metal finishing, construction, oil and gas, food, beverage, flavours, fragrance, pharmaceuticals, polymers, coatings, electronics, rubber and plastics (Source: H1 2026 news release, 13 Aug 2026; FY2024 news release, 20 Feb 2025). The interim financial statements give its principal activities as trading in chemicals and chemical-related products, contract manufacturing of chemicals, and investment holding (H1 2026 condensed interim FS, Note 1.1).
Business model and value-chain position
| Value chain step | What Megachem does |
|---|---|
| Purchase | Global sourcing network across China, Europe, Japan, the US and India. Sole-distributor appointments from several principals (the principals are not named). |
| Store | Own warehousing in Singapore, including the rebuilt Major Hazard Installation (MHI)-compliant warehouse at 132 Pioneer Road, which received its Temporary Occupation Permit in June 2026. Third-party warehouses are also used. |
| Vendor-managed inventory (VMI) and just-in-time delivery | Holds stock near customer production sites and delivers on demand. |
| Transport | Logistics coordination. |
| Custom blending / contract manufacturing | Mixing and blending to customer formulations, repackaging from bulk to smaller packs, filling, packaging and labelling. |
| Auxiliary services | Repacking, relabelling, lab analysis. |
| Technical support | Dedicated application laboratories. |
Megachem is a third-party distributor in the middle of the chemical value chain, between producers and chemical users. The company's own business-model graphic (FY2025 results presentation; AR2024 p.11) lists these value-adding steps:
Revenue model
| Revenue type | FY2025 SGD Mn | % of total | Nature |
|---|---|---|---|
| Distribution activity (sale of goods) | 121.1 | 97.4 | Margin on resale of third-party specialty chemicals. Transactional, spot and repeat orders. |
| Manufacturing activity (mainly custom-blending fees) | 3.3 | 2.6 | Service and toll fees. The company notes that manufacturing revenue consists mainly of custom-blending service fees. |
| Subscription / licensing | 0 | 0 | — |
Sources: FY2025 results presentation; H1 2026 condensed interim FS, Review of Performance (half-year distribution of S$62.3m in H1 2025 and S$58.8m in H2 2025; manufacturing of S$1.7m and S$1.5m).
Customer types and end-markets
| Industry cluster | Sub-applications (company list) | Share of FY2025 sales |
|---|---|---|
| Performance Coatings & Polymers | Paints and inks, polymerisation, adhesives, construction, textiles | 32% |
| Surface Technology | Electronics, metal finishing, industrial cleaning, water treatment, pulp and paper | 27% |
| Biotech | F&B, pharmaceuticals, nutraceuticals, cosmeceuticals, agriculture/feed, flavours and fragrances, homecare, photography | 21% |
| Advanced Polymer Composites | Rubber, plastics, polyurethane, polyester | 12% |
| Resources / Oil & Gas | Mining, oleochemicals, petrochemicals, lubricants and grease, oil field/refinery | 8% |
Customers: more than 2,000 industrial customers, which the company says are mainly multinationals. No single-customer concentration is disclosed. The risk section states there is no significant concentration of credit risk (H1 2026 FS, Risks).
End-market mix, FY2025: (FY2025 results presentation, "Sales Breakdown by Industry Coverage"):
Independent characterisation
Megachem is a sub-scale, Asia-centric, multi-principal specialty distributor. Its economics resemble a working-capital-intensive trading business, not a specialty producer. Gross margins sit at 24–26% in normal years, and EBITDA margins were 5–9% outside the fire year. Inventory takes about 115–170 days to turn, depending on the measure. The edge it claims (breadth of product range, VMI/JIT, sole distributorships, custom blending) is real but narrow. Earnings track chemical price cycles closely, as the FY2021–22 boom and the 2023 destocking slump show. Ownership is tightly held: the founder plus Chori control about two-thirds of the shares. This limits liquidity and takeover optionality, but it also shields a conservative, dividend-paying management culture. The 2023 fire and the rebuild dominated reported results until H1 2026. With the rebuilt warehouse now operating, the main near-term investment question is whether lower third-party warehousing costs (S$3.3–3.4m a year in FY2024–25) can lift margins in a structural way.
Strategy
Stated strategy themes
- Growth formula ("(CHemical)+Re(Action)2: for-Gr{OW}th"), AR2024: growth is built around three pillars — geographic network, product offerings and industry coverage. These are reinforced by supply-chain infrastructure and close customer and supplier relationships.
Two-pillar business model, AR2024 Risk Management: distribution and contract manufacturing are positioned as the twin growth engines. Diversification across markets, customers, products and suppliers is described as the core resilience strategy.
-
FY2026 "Unlocking our Potential" pillars, FY2025 results presentation:
-
High-growth markets: ASEAN countries such as Malaysia, Indonesia and Vietnam. The rationale given is tariff advantage, lower costs, a young population and a growing middle class, and rising FDI and production output.
-
High-growth industries: electronics, automotive, life sciences and materials science. This includes specialty chemicals for lightweight materials in EVs, electronics and robotics, and life-science chemicals driven by global ageing.
-
Management notes that China, the EU, ASEAN and India together account for about half of global manufacturing output and that Megachem is present in all four.
-
Operating priorities: prudent inventory management; operational and financial discipline; a shift towards specialty (rather than commodity) chemicals for margin stability (H1 2026 Prospects).
Strategic initiatives (last 24 months)
| Initiative | Status / detail | Source |
|---|---|---|
| Warehouse rebuild at 132 Pioneer Road | Budget about S$19m (S$16.2m construction). Funded by insurance, bank loans and internal funds. Temporary Occupation Permit June 2026. Designed for safety, MHI compliance and environmental performance. Capacity of more than 5,000 pallets; target about 70% of storage in-house. | AR2024; H1 2026 news release; The Edge (Aug 2025, Feb 2026) |
| Warehouse cost reduction | Moving inventory back from third-party warehouses is expected to significantly reduce storage costs (third-party storage was S$3.4m in FY2024 and S$3.3m in FY2025). | H1 2026 news release |
| Buy-out of minority interests | UK 85%→97% (Mar 2024); Megachem Raya group 74%→83% (Nov 2024) | AR2024 |
| EV materials exposure: JIOS Aerogel | US$1m preference-share investment by Megachem plus US$2m by Megachem Thailand. JIOS has a pilot plant in Singapore and reported a thermal-blade supply contract with an automaker. | 2026 AGM summary; PR Newswire 2023 |
| Associate diversification (Megachem Thailand, H1 2026) | 65% of SPD Biotech (pharma and medical distribution); US$2.5m preferred stake in Kyberlife (lab-equipment marketplace software); MGT Investment Pte Ltd (Singapore holding) | H1 2026 FS, Rule 706A |
| Sustainability reporting | Sustainability report, TCFD disclosure and GRI index in AR2024. Climate risk added as one of six enterprise risk management components. | AR2024 |
Medium-term targets and guidance
No quantitative medium-term financial targets or guidance are disclosed. The company states there was no forecast or prospect statement previously disclosed to shareholders (H1 2026 FS, Prospects). The only operational targets identified are improving the working-capital cycle (FY2025 results presentation) and the in-house storage ratio cited in broker coverage.
Products & Services
Disclosure limitation. Megachem does not publish a product-by-product catalogue, revenue by product line, principal or brand names, prices, or product launch years in its filings. It discloses its portfolio at the level of industry clusters and applications. The catalogue below is organised at the most granular level the company discloses. Product-level detail that is not disclosed is marked as such and has not been estimated.
Distribution segment: specialty chemicals by industry cluster
| Cluster | Application line | Description (company framing) | Target customer | Launch / version year | Pricing model | Named flagship products |
|---|---|---|---|---|---|---|
| Performance Coatings & Polymers (32% of FY2025 sales) | Paints and inks | Additives, resins and intermediates for paint and ink formulators | Paint and ink manufacturers | — | Transactional resale; price lists not disclosed | — |
| — | Polymerisation | Chemicals used in polymer production | Polymer producers | — | Transactional | — |
| — | Adhesives | Raw materials for adhesive formulations | Adhesive makers | — | Transactional | — |
| — | Construction | Construction-chemical inputs | Construction-chemical formulators | — | Transactional | — |
| — | Textiles | Textile processing chemicals | Textile mills / processors | — | Transactional | — |
| Surface Technology (27%) | Electronics | Specialty chemicals for electronics processing | Electronics and semiconductor-related manufacturers | — | Transactional / VMI | — |
| — | Metal finishing | Plating and surface-treatment chemicals | Metal finishers | — | Transactional | — |
| — | Industrial cleaning | Cleaning formulations and inputs | Industrial users | — | Transactional | — |
| — | Water treatment | Water treatment chemicals | Utilities, industrial plants | — | Transactional | — |
| — | Pulp and paper | Process chemicals | Paper mills | — | Transactional | — |
| Biotech (21%) | Food and beverages | Food-grade ingredients and additives | F&B manufacturers | — | Transactional | — |
| — | Pharmaceuticals | Pharma-grade chemicals and excipients | Pharma manufacturers | — | Transactional | — |
| — | Nutraceuticals / cosmeceuticals | Active and functional ingredients | Supplement and personal-care makers | — | Transactional | — |
| — | Agriculture / feed | Agrochemical and feed inputs | Agri and feed producers | — | Transactional | — |
| — | Flavours and fragrances; homecare; photography | Specialty ingredients | Formulators | — | Transactional | — |
| Advanced Polymer Composites (12%) | Rubber; plastics; polyurethane; polyester | Additives and intermediates for compounding and composite manufacture | Rubber, plastics and PU/polyester producers | — | Transactional | — |
| Resources / Oil & Gas (8%) | Mining; oleochemicals; petrochemicals; lubricants and grease; oil field / refinery | Process and performance chemicals | Resource and energy companies | — | Transactional | — |
Manufacturing segment and value-added services
| Offering | Description | Target customer | Pricing model |
|---|---|---|---|
| Contract manufacturing / custom blending | Blending to customer formulations so customers can outsource non-core production, including MNCs entering Asia without capex (AR2024, "Why Megachem") | MNC formulators | Service and toll fees (the bulk of manufacturing revenue) |
| Repackaging | Breaking bulk into smaller packaging | Small and medium customers | Fee / embedded margin |
| Filling, packaging, labelling | Finishing services | Formulators | Fee |
| Proprietary chemical products manufacturing | Mentioned as a capability in AR2024. The products are not named. | — | — |
| Vendor-managed inventory and just-in-time delivery | Megachem holds and manages stock near customer sites | Key accounts (MNCs) | Embedded in product margin |
| Technical support via application laboratories | Formulation and application support | All customers | Embedded |
| Lab analysis (third-party profile) | Craft.co's profile also lists endothermic and exothermic reaction capability, liquid–solid blending vessels and lab analysis. | — | — |
Associate-level offerings (Megachem Thailand group, 36.19% owned)
-
Specialty chemical distribution in Thailand (Megachem Thailand, Megachem Plus, Green Leaf Chemical).
-
Graphite products: Mega Fuji Graphite Ltd. Product detail is not publicly disclosed.
-
Pharmaceutical and medical product distribution, plus hospital and lab design consultancy: SPD Biotech, 65% acquired by Megachem Thailand in H1 2026 for THB1.3m (about S$51,000).
Financial Narrative
Basis. Sources are the company Financial Highlights (AR2024), FY2025 results presentation and H1 2026 FS, which are reported, and S&P Global Market Intelligence standardised statements via StockAnalysis.com, which are standardised. Where the two bases differ, the difference is noted. FY = fiscal year ended 31 December. All values are S$m unless stated.
Income statement
Notes:
-
Revenue CAGR FY2021–FY2025 is −2.7%. FY2020–FY2025 is +3.4%, from FY2020 revenue of S$105.2m (derived).
-
FY2023 gross profit includes S$5.9m of inventory written off in the fire. Adjusted FY2023 gross profit was S$28.5m (FY2024 results presentation).
-
FY2024 other income includes S$9.7m of insurance claims and a S$0.62m gain on sale of a Malaysian property. S&P classifies insurance outside operating income, which is why the S&P operating line is negative in FY2024.
-
FY2024 payout is calculated on adjusted NPAT.
Commentary. The five years contain one up-cycle (FY2021–22), one sharp down-cycle compounded by the fire (FY2023), and a muted recovery with distortions (FY2024–25). The underlying trend in adjusted profit is far weaker than the headline. Adjusted NPAT fell from S$8.0m (FY2021) to S$1.9m (FY2023) and recovered only to S$3.9m (FY2025), even though gross margin is now higher than in FY2021. The difference sits in operating expenses. Staff costs rose from about S$15.5m (FY2023) to S$17.0m (FY2024) and S$16.6m (FY2025). Third-party warehouse storage rose from S$2.7m (FY2023) to about S$3.3–3.4m a year after the fire. Finance costs peaked at S$2.0m in FY2023. The FY2025 gross margin gain to 25.6% came mainly from a lower allowance for inventory impairment, not from pricing (FY2025 results presentation). The inflection is H1 2026: gross margin reached 28.6% on higher chemical prices and an inventory-allowance write-back. EBITDA was S$6.4m in the half alone, close to the S$6.8m for all of FY2025.
Half-year progression: notes and sources
Sources: AR2024 Operating and Financial Review; FY2025 results presentation; H1 2026 FS. H1 2024 gross profit and the H1/H2 2024 EPS split are derived from the reported margins and full-year totals.
Fire incident: profit and loss impact by period
Cumulative to 30 June 2026, insurance income is S$13.667m against S$15.273m of expenses and losses (inventory S$5.919m; PPE S$0.811m; demolition S$3.351m; waste disposal S$3.665m; customer compensation S$0.805m; other S$0.722m). The net cumulative pre-tax hit is about S$1.6m, excluding reconstruction capex. Final insurance recoveries were still under negotiation as of the April 2026 AGM. Source: H1 2026 FS, Review of Performance; 2026 AGM summary.
Balance sheet (as at 31 December)
Sources: S&P via StockAnalysis.com for standardised lines; AR2024 Financial Highlights and FY2025 results presentation for borrowings, gearing and NAV. Latest position (30 June 2026): cash S$14.4m; borrowings S$39.4m (current S$33.2m, non-current S$6.2m); lease liabilities S$3.7m; total equity S$66.8m; NAV per share 48.75 cents; net gearing 0.38x; total assets S$125.8m.
Commentary. The balance sheet is conservative in leverage but heavy in working capital. Inventory peaked at S$49.3m in FY2022 during the restocking cycle and has been run down to S$29.0m. Borrowings are mainly short-term trade finance: bills payable of S$16.2m and short-term loans of S$15.6m at 30 June 2026. This means a high share of debt reprices or rolls within 12 months. The FY2025 step-up in long-term debt (S$6.25m) is the secured construction loan, mortgaged over the 132 Pioneer Road warehouse. PPE nearly doubled in FY2025 as the warehouse was capitalised, with S$14.28m of building cost capitalised by 30 June 2026. There is virtually no goodwill. Book value is tangible.
Cash flow
Source: S&P via StockAnalysis.com. Company-reported OCF matches: S$11.0m (FY2024) and S$5.6m (FY2025). H1 2026 OCF was S$1.3m, after S$3.9m of receivables build. H1 2026 capex was S$4.4m.
Commentary. Cash generation is countercyclical, which is typical of distributors. OCF was negative in the FY2021–22 boom as inventory and receivables ballooned (S$28m of working-capital absorption over two years). It turned strongly positive in the FY2023 destocking. Cumulative FY2021–FY2025 FCF was about −S$1.6m, while dividends paid totalled about S$8.7m. Dividends over the cycle have therefore been funded partly by debt. The FY2025 FCF deficit is almost entirely warehouse capex, which is one-off. With the rebuild largely complete (capital commitments S$2.1m at 30 June 2026), maintenance capex should normalise towards the S$1–3m historical range.
Ratios
Method notes:
-
ROIC = (PBT + finance costs) × (1 − effective tax rate) ÷ (total equity + total debt − cash).
-
EBIT = PBT + finance costs.
-
The FY2023 net debt/EBITDA value is negative because EBITDA was negative. It is not meaningful.
-
FY2024 ROE, ROA and ROIC are inflated by S$9.7m of insurance income.
-
The FY2021–FY2024 ROE values match the company-reported figures.
Company-reported working-capital turnover days
The company's day counts are higher than the year-end derived ones, likely because the company uses average balances or balances gross of allowance. The method is not disclosed. Both bases show a cash cycle of more than five months. H1 2026 company figures: inventory 140 days, receivables 72 days, payables 24 days. Management has stated a target to improve the working-capital cycle (FY2025 results presentation).
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment Overview
| Segment | Contents | Products / services |
|---|---|---|
Distribution | Trading of more than 1,000 specialty chemical types and grades across all subsidiaries | Specialty chemical resale, VMI, JIT delivery, technical support |
Manufacturing | Contract manufacturing and custom blending, principally in Singapore (Megachem Manufacturing Pte Ltd) | Blending to customer formulations, repacking, filling, labelling. Revenue is mainly service fees. |
Revenue by Segment and Segment Margins & Growth (%)
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Distribution revenue (SGD Mn) | 119.298 | 124.920 | 121.139 |
Manufacturing revenue (SGD Mn) | 3.711 | 3.922 | 3.273 |
Total revenue (SGD Mn) | 123.009 | 128.842 | 124.412 |
Distribution % of total | 97.0 | 97.0 | 97.4 |
Manufacturing % of total | 3.0 | 3.0 | 2.6 |
Distribution YoY growth (%) | -14.4 | 4.7 | -3.0 |
Manufacturing YoY growth (%) | -14.2 | 5.7 | -16.5 |
Revenue by Segment
| Metric | H1 2025 | H2 2025 | H1 2026 |
|---|---|---|---|
Distribution revenue (SGD Mn) | 62.328 | 58.811 | 64.176 |
Manufacturing revenue (SGD Mn) | 1.745 | 1.528 | 1.678 |
Distribution segment result (SGD Mn) | 1.949 | 2.0 | 4.227 |
Manufacturing segment result (SGD Mn) | 0.025 | 0.1 | 0.401 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansRevenue by Segment — Singapore
| Metric | H1 2025 | H1 2026 |
|---|---|---|
Singapore (SGD Mn) | 24.284 | 25.334 |
Malaysia (SGD Mn) | 7.136 | 5.854 |
United Kingdom (SGD Mn) | 9.319 | 10.292 |
China (SGD Mn) | 6.827 | 7.017 |
Middle East (SGD Mn) | 6.434 | 7.300 |
Others (SGD Mn) | 10.073 | 10.057 |
Total (SGD Mn) | 64.073 | 65.854 |
Group Entities
| Entity | Country | Function | Group interest |
|---|---|---|---|
Megachem Limited | Singapore | Parent; distribution; HQ | — |
Megachem Manufacturing Pte Ltd | Singapore | Contract manufacturing / blending | — |
Megachem Raya Pte Ltd and subsidiary | Singapore | Distribution | 83% (since Nov 2024; previously 74%) |
Megachem (Shanghai) Pte Ltd | Singapore | Holding for China | — |
Megachem International Trading (Shanghai) Co., Ltd | China | Distribution | — |
Megachem International Trading (Beijing) Co., Ltd | China | Sales office | — |
C.N. Chemicals Sdn Bhd | Malaysia | Distribution / warehousing | 100% (wholly owned per AR2024) |
P.T. Mega Kemiraya | Indonesia | Distribution | — |
Megachem Phils., Inc | Philippines | Distribution | — |
Megachem Vietnam Company Limited | Vietnam | Distribution | — |
Megachem (Myanmar) Limited | Myanmar | Distribution | — |
Megachem Specialty Chemicals (I) Private Limited | India | Distribution | Not publicly disclosed. Negative net tangible assets; parent provides financial support (S$0.905m undertaking at 30 Jun 2026). |
Megachem Middle East FZE | UAE (Jebel Ali Free Zone) | Distribution | — |
Megachem (UK) Ltd | United Kingdom | Distribution (Europe) | 97% (since Mar 2024; previously 85%) |
Megachem Australia Pty Ltd (formerly MG Chemicals (Australia) Pty Ltd) | Australia | Distribution | Not publicly disclosed. Negative net tangible assets; parent support undertaking S$1.159m. |
Megachem Plus Limited | Thailand | Distribution | — |
Megachem (Thailand) PCL (SET: MGT) | Thailand | Distribution; associate | 36.19% (associate, equity-accounted) |
Green Leaf Chemical Co., Ltd; Mega Fuji Graphite Ltd; SPD Biotech Co., Ltd (65%, acquired H1 2026); MGT Investment Pte Ltd | Thailand / Singapore | Subsidiaries of Megachem Thailand | Indirect, via the 36.19% associate (SPD about 23.52% indirect; MGT Investment about 36.19% indirect) |
“—” = not publicly disclosed.
Income Statement and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (SGD Mn) | 138.90 | 143.72 | 123.01 | 128.84 | 124.41 |
Revenue growth YoY (%) | 32.0 | 3.5 | -14.4 | 4.7 | -3.4 |
Cost of sales (SGD Mn) | 104.79 | 109.31 | 100.51 | 97.61 | 92.61 |
Gross profit (SGD Mn) | 34.11 | 34.41 | 22.50 | 31.23 | 31.80 |
Gross margin (%) | 24.6 | 23.9 | 18.3 | 24.2 | 25.6 |
Operating income, S&P standardised, excl. insurance and other income (SGD Mn) | 7.25 | 7.13 | -8.15 | -1.29 | 3.98 |
Operating margin, S&P basis (%) | 5.2 | 5.0 | -6.6 | -1.0 | 3.2 |
EBITDA, company-reported (SGD Mn) | 11.1 | 10.5 | -1.9 | 11.8 | 6.8 |
EBITDA margin (%) | 8.0 | 7.3 | -1.5 | 9.2 | 5.5 |
Finance costs (SGD Mn) | 0.80 | 1.38 | 2.04 | 1.91 | 1.41 |
Share of associates' profit (SGD Mn) | 1.61 | 1.12 | 1.17 | 1.22 | 1.17 |
Profit before tax (SGD Mn) | 9.19 | 7.83 | -5.34 | 8.69 | 4.27 |
Income tax (SGD Mn) | 1.20 | 1.76 | 0.46 | 0.78 | 0.36 |
Net profit after tax, group (SGD Mn) | 8.0 | 6.1 | -5.8 | 7.9 | 3.9 |
Net profit attributable to equity holders (SGD Mn) | 7.76 | 5.88 | -5.91 | 7.91 | 3.83 |
Adjusted NPAT excl. fire impact (SGD Mn) | 8.0 | 6.1 | 1.9 | 2.9 | 3.9 |
Net margin, attributable (%) | 5.6 | 4.1 | -4.8 | 6.1 | 3.1 |
EPS basic = diluted (S cents) | 5.82 | 4.41 | -4.43 | 5.93 | 2.88 |
Dividend per share (S cents) | 2.0 | 2.0 | 0.0 | 1.0 | 1.0 |
Dividend payout, company basis (%) | 34.4 | 45.4 | 0.0 | 46.0 | 34.8 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansIncome Statement and Margin Analysis (%) (Half-Yearly)
| Metric | H1 2024 | H2 2024 | H1 2025 | H2 2025 | H1 2026 |
|---|---|---|---|---|---|
Sales (SGD Mn) | 65.2 | 63.7 | 64.1 | 60.3 | 65.9 |
Gross profit (SGD Mn) | 15.5 | 15.7 | 16.1 | 15.7 | 18.8 |
Gross margin (%) | 23.8 | 24.7 | 25.1 | 26.1 | 28.6 |
EBITDA (SGD Mn) | 4.5 | 7.3 | 3.4 | 3.4 | 6.4 |
NPAT (SGD Mn) | 2.0 | 5.9 | 1.7 | 2.2 | 4.6 |
Adjusted NPAT excl. fire (SGD Mn) | 1.7 | 1.3 | 1.7 | 2.2 | 3.4 |
EPS (S cents) | 1.50 | 4.43 | 1.26 | 1.61 | 3.42 |
Key Financials
| Metric | H2 2023 | H1 2024 | H2 2024 | H1 2025 | H2 2025 | H1 2026 |
|---|---|---|---|---|---|---|
Insurance claims income (SGD K) | 3,149 | 4,910 | 4,408 | 0 | 0 | 1,200 |
Total fire-related expenses / losses (SGD K) | -10,887 | -4,188 | -198 | 0 | 0 | 0 |
Net impact before tax (SGD K) | -7,738 | 722 | 4,210 | 0 | 0 | 1,200 |
Balance Sheet and Per-Share Data
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Total assets (SGD Mn) | 110.93 | 117.09 | 100.24 | 104.53 | 115.01 |
Cash and short-term investments (SGD Mn) | 12.08 | 11.93 | 13.63 | 15.97 | 14.01 |
Inventories (SGD Mn) | 36.45 | 49.34 | 33.56 | 31.74 | 29.04 |
Trade receivables (SGD Mn) | 30.58 | 27.03 | 22.98 | 22.87 | 23.57 |
Property, plant and equipment incl. right-of-use (SGD Mn) | 18.02 | 17.95 | 16.98 | 19.16 | 32.71 |
Investments in associates and other LT investments (SGD Mn) | 7.97 | 7.90 | 9.74 | 10.70 | 11.58 |
Goodwill and intangibles (SGD Mn) | 0.03 | 0.03 | 0.02 | 0.03 | 0.03 |
Bank borrowings excl. leases, company-reported (SGD Mn) | 28.9 | 36.4 | 28.5 | 25.2 | 34.7 |
Short-term debt incl. current leases (SGD Mn) | 27.90 | 35.76 | 28.32 | 25.60 | 28.76 |
Long-term debt incl. non-current leases (SGD Mn) | 4.00 | 3.32 | 3.07 | 2.75 | 8.95 |
Total debt incl. leases (SGD Mn) | 31.89 | 39.09 | 31.39 | 28.35 | 37.71 |
Net debt incl. leases (SGD Mn) | 19.81 | 27.15 | 17.76 | 12.38 | 23.71 |
Equity attributable to owners (SGD Mn) | 57.26 | 58.59 | 49.96 | 58.55 | 61.31 |
Non-controlling interests (SGD Mn) | 3.13 | 3.15 | 3.20 | 1.95 | 1.75 |
Total equity (SGD Mn) | 60.39 | 61.74 | 53.16 | 60.49 | 63.06 |
Working capital (SGD Mn) | 37.66 | 38.94 | 29.04 | 32.83 | 27.24 |
NAV per share (S cents) | 42.95 | 43.96 | 37.48 | 43.92 | 46.00 |
Gearing, company basis (x) | 0.51 | 0.62 | 0.57 | 0.43 | 0.57 |
Net gearing, company basis (x) | 0.30 | 0.42 | 0.30 | 0.16 | 0.34 |
Cash Flow and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Operating cash flow (SGD Mn) | -7.86 | -2.97 | 15.82 | 11.05 | 5.65 |
Change in working capital (SGD Mn) | -16.38 | -11.95 | 10.55 | -0.13 | -0.06 |
Capital expenditure (SGD Mn) | -3.42 | -1.66 | -1.19 | -2.74 | -14.24 |
Free cash flow (SGD Mn) | -11.29 | -4.64 | 14.64 | 8.31 | -8.59 |
Free cash flow margin (%) | -8.1 | -3.2 | 11.9 | 6.5 | -6.9 |
Dividends paid to equity holders (SGD Mn) | -2.40 | -2.67 | -1.60 | -0.67 | -1.33 |
Share buybacks (SGD Mn) | 0 | 0 | 0 | 0 | 0 |
Net debt issued / (repaid) (SGD Mn) | 8.84 | 6.95 | -8.07 | -3.82 | 9.62 |
Cash interest paid (SGD Mn) | 0.64 | 1.05 | 1.94 | 1.77 | 1.27 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
ROE, attributable NPAT / year-end equity (%) | 13.6 | 10.0 | -11.8 | 13.5 | 6.2 |
ROA, attributable NPAT / total assets (%) | 7.0 | 5.0 | -5.9 | 7.6 | 3.3 |
ROIC, derived (%) | 10.8 | 8.0 | -4.7 | 13.2 | 6.0 |
Current ratio (x) | 1.81 | 1.75 | 1.67 | 1.80 | 1.64 |
Debt / equity incl. leases (x) | 0.53 | 0.63 | 0.59 | 0.47 | 0.60 |
Net debt / EBITDA (x) | 1.78 | 2.59 | -9.35 | 1.05 | 3.49 |
Interest coverage, EBIT / finance costs (x) | 12.5 | 6.7 | -1.6 | 5.5 | 4.0 |
Asset turnover, revenue / total assets (x) | 1.25 | 1.23 | 1.23 | 1.23 | 1.08 |
Inventory days, year-end inventory / COGS × 365 (derived) | 127 | 165 | 122 | 119 | 114 |
Receivable days, year-end AR / revenue × 365 (derived) | 80 | 69 | 68 | 65 | 69 |
Payable days, year-end AP / COGS × 365 (derived) | 29 | 23 | 26 | 24 | 24 |
Cash conversion cycle, derived (days) | 178 | 211 | 164 | 160 | 159 |
Working Capital (Days)
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Inventory turnover (days) | 170 | 147 | 147 |
Trade receivables turnover (days) | 76 | 66 | 69 |
Trade payables turnover (days) | 35 | 27 | 26 |
Cash conversion cycle, derived from company days | 211 | 186 | 190 |
Revenue by Region
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
ASEAN (SGD Mn) | 72.226 | 74.252 | 68.123 |
Europe (SGD Mn) | 15.704 | 16.284 | 16.100 |
North Asia (SGD Mn) | 10.316 | 12.451 | 15.875 |
Middle East (SGD Mn) | 10.559 | 10.987 | 11.571 |
Australia (SGD Mn) | 9.692 | 10.216 | 8.464 |
South Asia (SGD Mn) | 3.820 | 4.246 | 3.764 |
America (SGD Mn) | 0.212 | 0.166 | 0.258 |
Africa (SGD Mn) | 0.480 | 0.240 | 0.257 |
Total (SGD Mn) | 123.009 | 128.842 | 124.412 |
Geographic Revenue
| Metric | FY2024 YoY (%) | FY2025 YoY (%) | FY2025 share (%) |
|---|---|---|---|
ASEAN | 2.8 | -8.3 | 54.8 |
Europe | 3.7 | -1.1 | 12.9 |
North Asia | 20.7 | 27.5 | 12.8 |
Middle East | 4.1 | 5.3 | 9.3 |
Australia | 5.4 | -17.1 | 6.8 |
South Asia | 11.2 | -11.4 | 3.0 |
America | -21.7 | 55.4 | 0.2 |
Africa | -50.0 | 7.1 | 0.2 |
Geographic Revenue (Half-Yearly)
| Metric | H1 2025 | H2 2025 | H1 2026 |
|---|---|---|---|
ASEAN | 35,594 | 32,529 | 36,126 |
Europe | 8,487 | 7,613 | 9,249 |
North Asia | 7,784 | 8,091 | 7,469 |
Middle East | 6,388 | 5,183 | 7,031 |
Australia | 3,722 | 4,742 | 3,769 |
South Asia | 1,769 | 1,995 | 1,626 |
America | 209 | 49 | 257 |
Africa | 120 | 137 | 327 |
Total | 64,073 | 60,339 | 65,854 |
Share Price History
| Date | Price | Source |
|---|---|---|
17 Oct 2003 (IPO) | 0.280 | Company |
30 Jun 2024 | 0.470 | H1 2024 presentation (yield calculation) |
31 Dec 2024 | 0.430 | AR2024 (yield calculation) |
19 Feb 2025 | 0.395 | AR2024 |
8 Sep 2025 | 0.450 | GuruFocus dividend event log |
31 Dec 2025 | 0.420 | FY2025 presentation (yield calculation) |
23 Feb 2026 | 0.420 | FY2025 presentation |
6 Jul 2026 | 0.490 | StockAnalysis.com |
4 Sep 2026 | 0.490 | StockAnalysis.com |
5 Oct 2026 | 0.450 | StockAnalysis.com |
Valuation Multiples
| Multiple | Megachem | Basis |
|---|---|---|
Market capitalisation | S$60.0m | 133.3m shares |
Enterprise value | about S$90.5m | Market cap + borrowings S$39.4m + leases S$3.7m + NCI S$1.8m − cash S$14.4m (30 Jun 2026) |
P/E, trailing 12 months reported | 8.9x | TTM EPS 5.03 cents (H2 2025 1.61 + H1 2026 3.42) |
P/E, TTM excluding insurance | about 10.9x | TTM adjusted EPS about 4.13 cents |
P/E, FY2025 | 15.6x | FY2025 EPS 2.88 cents |
EV/EBITDA, TTM | 9.2x | TTM EBITDA S$9.8m (H2 2025 3.4 + H1 2026 6.4) |
EV/EBITDA, TTM excluding insurance | about 10.5x | Adjusted TTM EBITDA about S$8.6m |
EV/Sales, TTM | 0.72x | TTM sales S$126.2m (GuruFocus shows 0.73x) |
P/B | 0.92x | NAV 48.75 cents (30 Jun 2026) |
Dividend yield, trailing | 2.2% | 1.0 cent over the last 12 months |
Analyst Ratings & Targets
| Broker | Date | Rating | Target price |
|---|---|---|---|
SAC Advisors / SAC Capital | Jun 2018 | Buy (initiation) | 50 cents |
SAC Capital | Aug 2021 | Buy | 55 cents |
SAC Capital | Jun–Aug 2022 | Buy | 58 cents |
SAC Capital | Aug 2025 | Hold | 50 cents (from 39 cents) |
Per-Share Data
| Metric | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Dividend per share (S cents) | 1.20 | 1.20 | 1.50 | 1.50 | 1.50 | 2.00 | 2.00 | 0.00 | 1.00 | 1.00 |
Bucket Details
| Bucket | SGD Mn | Detail |
|---|---|---|
Within 12 months | 33.19 | Bills payable S$16.21m; short-term loans S$15.63m (S$3.0m secured); current portion of long-term loans S$1.00m (secured); overdraft S$0.34m |
After 12 months | 6.18 | Long-term loans: S$5.75m secured on the warehouse; S$0.43m unsecured |
Lease liabilities | 3.68 | Current S$0.50m; non-current S$3.18m |
Total borrowings excluding leases | 39.37 | — |
Analyst Conclusions
Management guidance
-
No numerical guidance. The H1 2026 prospects statement expects the global outlook for H2 2026 to remain fragile, with Middle East tensions weighing. It expects moderate growth supported by AI and technology sectors, and continuing chemical-industry pressure from volatile feedstock prices and supply-chain disruption.
-
Megachem plans to:
-
stay focused on specialty chemicals for margin stability;
-
capture significant warehousing cost savings from the new facility;
-
maintain prudent inventory and financial management.
-
Consensus expectations
-
None available.
-
Stockopedia lists FY2026E and FY2027E columns, but the underlying estimates were not visible.
Bull case
-
Structural cost tailwind. Third-party storage of S$3.3–3.4m a year should fall sharply from H2 2026 now that inventory has moved back into the owned warehouse. That alone could add up to about S$2m a year to EBITDA (derived; partly offset by about S$0.4–0.5m of extra depreciation each half). On top of H1 2026's adjusted NPAT of S$3.4m, FY2026 adjusted NPAT of about S$6–7m (EPS about 4.5–5.3 cents) looks plausible. At that level the stock would trade at about 9–10x.
-
Margin regime change. Gross margin has risen for five consecutive halves, from 23.8% to 28.6%. The rise came from mix (Biotech plus Surface Technology are 48% of sales) and from higher prices, not only one-offs.
-
Asset backing plus optionality. The stock trades at 0.92x NAV, and that NAV includes a newly built Singapore hazardous-goods warehouse at cost. Further optionality comes from unsettled insurance recoveries, the JIOS Aerogel stake, and the 36.19% Thai associate. The SET-listed associate's market cap of about THB676–784m implies a look-through value of roughly S$9–11m at prevailing THB rates. This is approximate and FX-dependent.
Bear case
-
Revenue has not grown. FY2025 revenue is 13% below FY2022 and below FY2021, and the five-year CAGR is negative. The core ASEAN market fell 8.3% in FY2025. Cost savings cannot compound if the top line is stuck.
-
Cash generation is weak and debt is short-dated. Cumulative five-year FCF is negative. Borrowings have risen to S$39.4m (net gearing 0.38x), 84% due within 12 months. H1 2026 OCF of S$1.3m on S$5.0m of PBT shows how working capital absorbs profits in any upturn.
-
Governance and liquidity discount is likely to persist. About two-thirds of shares are held by the MD and Chori. Dissent ran at 22–34% at the 2026 AGM. Dividends were cut from 2.0 cents (FY2022) to 1.0 cent despite shareholder pushback. The only research comes from the sponsor, so the stock has few natural re-rating catalysts.
Catalysts and things to monitor (next 12 months)
FY2026 results (around Feb 2027): the first full half of in-house warehousing (H2 2026), and whether warehouse storage charges, about S$1.6m a half, fall materially.
Final insurance settlement: whether further recoveries are announced.
Gross margin durability above 27%: as H1 2026 price support fades.
Middle East and Europe momentum: versus Gulf-conflict disruption.
- Inventory days (target below 140) and receivable days (72 in H1 2026), to see whether OCF recovers.
Any change in Chori's stake or in the co-founder's 19% block: A block sale or a take-private would be the largest potential re-rating event.
FY2026 dividend: whether it returns towards 1.5–2.0 cents.
Status of the former executive director's claims: - Further insider buying by the MD, following the Sep 2026 filings.
Concluding analyst verdict
Megachem is a well-run but structurally sub-scale specialty chemicals distributor. Its investment case for the next 12–18 months rests more on cost normalisation than on growth. The July 2023 fire distorted three years of reported earnings: a S$5.8m loss in FY2023, a S$7.9m insurance-inflated profit in FY2024, and a S$3.9m profit in FY2025 weighed down by stopgap warehousing costs. With the Pioneer Road warehouse operating from June 2026, H1 2026 gives the clearest view so far of underlying earnings power. Adjusted NPAT was S$3.4m in a single half, EBITDA was S$6.4m and gross margin was 28.6%, all better than any half since 2022.
Against that, the top line is the weak point. Revenue of S$124m sits within a band the company first reached a decade ago. ASEAN, more than half of sales, contracted in FY2025. Parent-level M&A over five years amounted to minority buy-outs. Larger rivals such as Brenntag, IMCD and Azelis earn EBITDA margins about 1.5–2.3 times higher and are consolidating principal mandates across Asia, which is a slow-moving threat to an unnamed-principal model.
The balance sheet is sound on gearing but not on duration. Most debt is trade finance rolling within a year, and working capital absorbs cash whenever sales grow. Governance is orderly, with an independent chairman and a refreshed board, but control is concentrated. Dissent at the 2026 AGM points to unresolved friction with part of the shareholder base.
At S$0.45 the shares trade at about 0.9x NAV, about 11x trailing adjusted earnings and about 10x adjusted EV/EBITDA. That leaves room for upside if warehouse savings take adjusted FY2026 earnings towards 5 cents per share. It offers little protection if chemical pricing softens again. The overall stance is neutral with a positive operational bias. The key evidence will be the H2 2026 cost line and FY2026 operating cash flow.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Appointed | Age (per AR2024, early 2025) | Education | Prior / other roles |
|---|---|---|---|---|---|
Yeo Wee Kiong | Independent and Non-Executive Chairman; Chair of Nominating Committee; member of Audit and Remuneration Committees | 20 Apr 2024 | 69 | Barrister-at-Law (Lincoln's Inn); MBA (NUS); LLB Hons (London); B.Eng Mech Hons (NUS) | Directorships at AF Global, Pacific Century Regional Development, SUTL Enterprise; past boards include Roxy-Pacific, Asian Healthcare Specialists |
Sidney Chew Choon Tee | Managing Director (the CEO-equivalent); Chair of Executive Committee; member of Nominating Committee | Director since 28 Apr 1989; MD since 9 Nov 2005 | 64 | B.Sc Chemistry (Hons); BA Business Administration | Co-founder. Executive Chairman until 1 Mar 2020. Director of Megachem Thailand PCL and most subsidiaries. Re-elected 28 Apr 2026. |
Sim Guan Seng | Independent Director; Chair of Audit Committee; member of Nominating and Remuneration Committees | 20 Apr 2024 | 65 | B.Acc Hons (NUS); FCCA; Certified Internal Auditor | MD of Cohen Assurance PAC since 2022; partner at Baker Tilly TFW 2004–2022; boards of Darco Water Technologies and Sitra Holdings |
Daniel Loh Hong Chye | Independent Director; Chair of Remuneration Committee; member of Audit Committee | 20 Apr 2024 | 58 | MBA (Oklahoma City University); B.Eng Mech (NUS) | MD and President Chemicals Asia, HELM Asia (Aug 2019–May 2023); President Director, BASF Indonesia; MD, BASF Malaysia |
Yasutaka Kawamura | Non-Executive, Non-Independent Director (Chori nominee) | 1 Jul 2020 | 54 | MBA; B.Econ | Executive Officer and Deputy GM, Corporate Planning, Chori Co., Ltd; President, Chori Machinery. Re-elected 28 Apr 2026. |
Executive Leadership Team
| Name | Title | Tenure | Background |
|---|---|---|---|
Sidney Chew Choon Tee | Managing Director | Co-founder, 1988 | See above |
Francis Yau Thiam Hwa | Chief Financial Officer | Joined 2000; CFO since 1 Jan 2007 | Former corporate banker; BBA (Finance) NUS; ISCA member. Independent director of one other SGX-listed company. |
Kwok Hwee Peng | Group Finance Manager and Company Secretary | Joined 2002; GFM since 2008 | Ex-PricewaterhouseCoopers; B.Acc NTU; ISCA member |
Peck Jen Jen | Joint Company Secretary | Since 15 Aug 2024 | — |
Board & Management Changes
| Date | Change |
|---|---|
1 Mar 2019 | Yokogawa (Chori) resigns; Sakoda (Chori) appointed |
1 Mar 2020 | Chew steps down as Executive Chairman; Lee Bon Leong becomes Independent Chairman |
1 Jul 2020 | Kawamura (Chori) appointed |
19 Apr 2023 | Co-founder Tan Bock Chia retires from the board |
19–20 Apr 2024 | Lee Bon Leong, Chan Kam Loon and Tay Kin Bee retire; Yeo, Sim and Loh appointed |
15 Aug 2024 | Peck Jen Jen replaces Hon Wei Ling as Joint Company Secretary |
28 Apr 2026 | Chew and Kawamura re-elected, each with 22.32% of votes cast against |
Major Shareholders
| Holder | Shares | % of 133.3m | As at / source |
|---|---|---|---|
Sidney Chew Choon Tee (direct and deemed) | 48,267,012 | 36.21 | 10 Mar 2025 (AR2024). Further purchases filed Sep 2026; updated total not captured. |
Chori Co., Ltd (held via custodian / nominee) | 39,976,670 | 29.99 | AGM results 2018–2024; AR2024 |
Tan Bock Chia (co-founder, former director) | 25,435,083 | 19.08 | — |
Implied free float (residual) | about 19,600,000 | about 14.7 | Derived, if the Tan holding is unchanged |
Competitive Landscape
Key Competitors
| Competitor | Type | Overlap with Megachem | Scale indicator | Relative positioning |
|---|---|---|---|---|
Brenntag SE (Germany) | Global #1 chemical distributor | All clusters; strong in APAC | FY2025 sales €15.2bn; operating EBITDA €1.29bn (8.5% margin) | Roughly 100x Megachem's revenue; full-line industrial plus specialties |
IMCD N.V. (Netherlands) | Global specialty distributor | Coatings, pharma, food, personal care in APAC | FY2025 operating EBITA €498m (−6%). Revenue rose slightly versus FY2024; the exact FY2025 figure was not captured. | Asset-light, M&A-driven; seven acquisitions in 2025, including in Korea and China |
Azelis Group (Belgium) | Global specialty distributor | Life sciences, coatings and industrial in APAC | FY2025 revenue €4.1bn; adjusted EBITDA €239m (12.8% margin) | Specialty-focused, roughly double Megachem's EBITDA margin |
Univar Solutions (US; private since 2023) | Global distributor | Industrial and specialty in APAC | — | Large full-line competitor |
DKSH (Switzerland), Performance Materials unit | Market-expansion services | Specialty chemicals in ASEAN | — | Strong ASEAN footprint |
Nagase & Co. (Japan) | Japanese chemical trading house | Specialty chemicals in Asia | — | Japanese principal relationships |
Connell Bros. (Wilbur-Ellis group) | Asia-Pacific specialty distributor | Coatings, food and personal care in ASEAN | Not publicly disclosed (private) | Direct regional peer |
Behn Meyer (Germany/Asia) | SE Asia specialty distributor | Coatings, polymers and agri in ASEAN | Not publicly disclosed (private) | Direct regional peer |
Jebsen & Jessen Chemicals | Asian distributor | Industrial and specialty chemicals in SE Asia | Not publicly disclosed (private) | Regional peer |
HELM AG / HELM Asia (Germany) | Chemical marketing and distribution | Industrial chemicals in Asia | — | Independent director Daniel Loh previously led HELM Asia |
Redox Limited (Australia) | Chemical distributor | Australia and Asia | — | Competes in Australia, where Megachem's sales fell 17.1% in FY2025 |
Chori Co., Ltd (Japan) | Trading house | Chemicals trading | — | Shareholder and partner, and a potential competitor |
“—” = not publicly disclosed.
Peer Comparison FY2025
| Metric | Megachem | Brenntag | Azelis | IMCD |
|---|---|---|---|---|
Revenue | S$124.4m | €15.2bn | €4.1bn | Not captured (slight increase reported) |
Revenue growth (reported currency) | -3.4% | -3.7% | -2.4% | Slight increase; −3% FX impact |
EBITDA margin | 5.5% | 8.5% (operating EBITDA) | 12.8% (adjusted EBITDA) | Not captured (EBITA €498m) |
Gross margin | 25.6% | Not captured | Not captured | Not captured |
R&D intensity | Not disclosed (nil reported) | — | — | — |
Acquisitions in 2025 | None at parent level | Not captured | 4 (prior-year revenue over €110m) | 7 |
“—” = not publicly disclosed.



